High molecular response rate of polycythemia vera patients treated with pegylated interferon α-2a

Blood

Volumn 108, Issue 6, 2006, Pages 2037-2040

  Kiladjian, Jean Jacques ^b   Cassinat, Bruno ^b   Turlure, Pascal ^b   Cambier, Nathalie ^b   Roussel, Murielle ^b   Bellucci, Sylvia ^b   Menot, Marie Laurence ^b   Massonnet, Gerald ^b   Dutel, Jean Luc ^b   Ghomari, Kamel ^b   Rousselot, Philippe ^b   Grange, Marie Jose ^b   Chait, Yasmina ^b   Vainchenker, William ^b   Parquet, Nathalie ^b   Abdelkader Aljassem, Lina ^b   Bernard, Jean François ^b   Rain, Jean Didier ^b   Chevret, Sylvie ^b   Chomienne, Christine ^b   Fenaux, Pierre ^a   more..

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULAR MARKER; PEGINTERFERON ALPHA2A;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CLONE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TARGETING; FEMALE; HOMOZYGOSITY; HUMAN; HYPOTHESIS; MALE; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; MUTATION; MUTATIONAL ANALYSIS; PHASE 2 CLINICAL TRIAL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; WILD TYPE;

EID: 33746059048     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-03-009860     Document Type: Article

References (16)

1. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
2. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148.
3. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
4. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
5. Vainchenker W, Constantinescu SN. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. Hematology. 2005;195-200.
6. Passamonti F, Rumi E, Pietra D, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation and constitutive mobilization of CD34-positive cells into peripheral blood in myeloproliferative disorders. Blood. 2006;107:3676-3682.
7. Silver RT. Interferon alfa: effects of long-term treatment for polycythemia vera. Semin Hematol. 1997;34:40-50.
8. Messora C, Bensi L, Vecchi A, et al. Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha. Br J Haematol. 1994;86:402-404.
9. Jones AV, Silver RT, Waghorn K, et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood. 2006;107:3339-3341.
10. Bukowski RM, Tendler C, Cutler D, Rose E, Laughlin MM, Statkevich P. Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer. 2002;95:389-396.
11. Perry CM, Jarvis B. Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C. Drugs. 2001;61:2263-2288.
12. Alvarado Y, Cortes J, Verstovsek S, et al. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol. 2003;51:81-86.
13. Langer C, Lengfelder E, Thiele J, et al. Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study. Haematologica. 2005;90:1333-1338.
14. James C, Delhommeau F, Marzac C, et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia. 2006;20:350-353.
15. Massaro P, Foa P, Pomati M, et al. Polycythemia vera treated with recombinant interferon-alpha 2a: evidence of a selective effect on the malignant clone. Am J Hematol. 1997;56:126-128.
16. Spivak JL. The optimal management of polycythaemia vera. Br J Haematol. 2002;116:243-254.